Blueprint Medicines (BPMC) Files $100M IPO

Blueprint Medicines Corporation (Nasdaq: BPMC) filed a registration with the U.S. SEC for an IPO of its Common Stock. The proposed maximum offering price is $100 million. The company plans to list on the Nasdaq under the symbol BPMC.

Goldman, Sachs & Co., Cowen and Company, JMP Securities, and Wedbush PacGrow.

Blueprint Medicines a biopharmaceutical company focused on improving the lives of patients with genomically defined diseases driven by abnormal kinase activation.

You May Also Be Interested In

• ZincFive to go public via $752 million SPAC deal with Spark I
• Rein Therapeutics expands Phase 2 trial to UK, enrolls 16 patients
• Vivos Therapeutics plans rights offering to raise capital